Literature DB >> 25252736

[Prognostic and predictively relevant factors for multiple sclerosis].

B Tackenberg1, T Schneider-Hohendorf, A Müller, J Schodrowski, H Wiendl.   

Abstract

The immunotherapy of multiple sclerosis (MS) is currently one of the most dynamic fields in clinical neurology. The comprehensive number of well-established and new innovative treatment options are a challenge for an intensive preoccupation with the differential indications and an activity-driven treatment control. In this context this review summarizes the known predictors of the natural course of MS and gives a review of challenges to be expected in association with predictors of treatment control.

Entities:  

Mesh：

Year:  2014        PMID： 25252736     DOI： 10.1007/s00115-014-4062-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  52 in total

1.  A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials.

Authors:  M P Amato; G Ponziani; M L Bartolozzi; G Siracusa
Journal:  J Neurol Sci       Date:  1999-10-15       Impact factor: 3.181

2.  Rising incidence of multiple sclerosis in females associated with urbanization.

Authors:  D Kotzamani; T Panou; V Mastorodemos; M Tzagournissakis; H Nikolakaki; C Spanaki; A Plaitakis
Journal:  Neurology       Date:  2012-05-16       Impact factor: 9.910

Review 3.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

4.  Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis.

Authors:  G Dean; M Elian
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-11       Impact factor: 10.154

5.  Sibling disability risk at onset and during disease progression in familial multiple sclerosis.

Authors:  Anne Wellek; Catharina Korsukewitz; Jan P Bach; Sabine Schock; Christian Eienbröker; Florian Seitz; Anna Spengler; Bernhard Hemmer; Kerstin Schlegel; Wolfgang H Oertel; Norbert Sommer; Björn Tackenberg
Journal:  Mult Scler       Date:  2011-05-11       Impact factor: 6.312

6.  Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Authors:  H-P Hartung; M S Freedman; C H Polman; G Edan; L Kappos; D H Miller; X Montalbán; F Barkhof; J Petkau; R White; V Sahajpal; V Knappertz; K Beckmann; V Lanius; R Sandbrink; C Pohl
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

7.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

Authors:  C Confavreux; M Hutchinson; M M Hours; P Cortinovis-Tourniaire; T Moreau
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

Review 8.  Prognostic factors in multiple sclerosis.

Authors:  Roberto Bergamaschi
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

Review 9.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

10.  Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D.

Authors:  Sreeram V Ramagopalan; Narelle J Maugeri; Lahiru Handunnetthi; Matthew R Lincoln; Sarah-Michelle Orton; David A Dyment; Gabriele C Deluca; Blanca M Herrera; Michael J Chao; A Dessa Sadovnick; George C Ebers; Julian C Knight
Journal:  PLoS Genet       Date:  2009-02-06       Impact factor: 5.917
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.